"10.1371_journal.pone.0050767","plos one","2012-12-10T00:00:00Z","Cuiqing Liu; Rajagopal Desikan; Zhekang Ying; Liubov Gushchina; Thomas Kampfrath; Jeffrey Deiuliis; Aixia Wang; Xiaohua Xu; Jixin Zhong; Xiaoquan Rao; Qinghua Sun; Andrei Maiseyeu; Sampath Parthasarathy; Sanjay Rajagopalan","Department of Physiology, Hangzhou Normal University, Hangzhou, China; Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, United States of America; InVasc Therapeutics, Tucker, Georgia, United States of America","Conceived and designed the experiments: CL ZY SP SR. Performed the experiments: CL ZY LG TK JD AW XX AM. Analyzed the data: JZ XR. Contributed reagents/materials/analysis tools: RD. Wrote the paper: CL QS SR.","The authors would like to acknowledge that this work was made possible via a collaborative effort between InVasc Therapeutics and Ohio State University. InVasc Therapeutics is a non-publicly traded private company based in Columbus, OH. Dr. Rajagopal Desiakan, one of the co-authors, was fully employed by InVasc Therapeutics at the time of this work. Cuiqing Liu was a co-founder of the company along with Sampath Parthasarathy and have patents on INV315 and related myeloperoxidase inhibitors that are currently pending approval at the US Patent and Trade office. The molecules that were investigated in this work were licensed for use by InVasc Therapeutics. Funding for this work was through a National Institutes of Health SBIR grant (R43HL103269) awarded to InVasc Therapeutics with OSU as a subcontractor. Neither Dr. Parthasarathy nor Cuiqing Liu are employees of InVasc but do function in an advisory role to the company. The authors declare that the relationship with InVasc does not alter their adherence to all of the PLOS ONE policies on sharing data and materials.","2012","12","Cuiqing Liu","CL",14,TRUE,4,8,2,3,TRUE,FALSE,FALSE,0,NA,FALSE
